Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025
Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Years.
Abstract readRandomized Controlled TrialClinical Trial, Phase IIIMulticenter Study
In one paragraph
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Total neoadjuvant chemotherapy combined with PD‑1 blockade and IL‑2 in MSS/pMMR locally advanced rectal cancer: short-term results of a prospective, single-arm phase II study.Signal transduction and targeted therapy · 2026Trial
- Clinical Benefit and Cost-Effectiveness of FOLFOX Versus LCCRT in Neoadjuvant Treatment for Patients with Locally Advanced Rectal Cancer: An Economic Analysis of the FOWARC and PROSPECT Trial.Annals of surgical oncology · 2026Trial
- Short-Course Radiotherapy-Based Total Neoadjuvant Therapy plus Tislelizumab for Locally Advanced Rectal Cancer (Neo-STAR): Early Outcomes of a Randomized Phase II Trial.Cancer communications (London, England) · 2026Trial
- Overweight BMI compromises survival and correlates with aggressive phenotypes in early-onset but not late-onset rectal cancer patients.The oncologist · 2026Article
- Low-intensity induction chemotherapy before chemoradiotherapy for rectal cancer: 10-year overall survival in the LARC-RRP trial.The British journal of radiology · 2026Article
- Impacts of neoadjuvant therapy on subsequent surgical difficulty, safety, and outcomes in locally advanced rectal cancer: a narrative review.Journal of gastrointestinal oncology · 2026Review
- Paradigm Shifts in Perioperative Management of Colorectal Cancer: Personalization Based on Tumor Biology, Primary Site, and Recurrence Risk, and the Evolving Role of Organ Preservation.International journal of molecular sciences · 2026Review
- NF-κB-active tumors with matrix CAFs and suppressive immunity as key resistance mechanisms to chemoradiation in rectal cancer.Experimental & molecular medicine · 2026Article
- Targeting Tex10 Overcomes Oxaliplatin Resistance by Competitively Disrupting the Non-Canonical BAF Complex in Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Report from the 27th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Colorectal Cancer, Calgary, Alberta, 26-27 September 2025: Advances in Colon and Rectal Cancer.Current oncology (Toronto, Ont.) · 2026Article
- [Neoadjuvant chemotherapy versus chemoradiotherapy in rectal cancer without involvement of the mesorectal fascia-Implications of CONVERT for radiation oncology?]Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Total Neoadjuvant Therapy, Organ Preservation and Beyond: A State-of-the-Art Systematic Review and Critical Appraisal of Locally Advanced Rectal Cancer Management.Diseases (Basel, Switzerland) · 2026Review
- Personalised neoadjuvant therapy, based on tumour characteristics and patient choice, is the best way forward in rectal cancer.Journal of gastrointestinal oncology · 2026Article
- Neoadjuvant FOLFOXIRI chemotherapy with or without camrelizumab in the treatment of locally advanced rectal cancer: a retrospective cohort study.NPJ precision oncology · 2026Article
- Predictors of survival for locally advanced rectal cancer patients with poor response to neoadjuvant chemoradiotherapy.Radiation oncology (London, England) · 2026Article
- Multiparametric MRI radiomics nomogram predicts synchronous distant metastasis in rectal cancer.Scientific reports · 2026Article
- A Review on the Evolving Role of Radiation Therapy in the Treatment of Locally Advanced Rectal Cancer.Current oncology (Toronto, Ont.) · 2025Review
- Neoadjuvant Treatment for Locally Advanced Rectal Cancer: Current Status and Future Directions.Cancers · 2025Review
- Immunotherapy versus chemotherapy as adjuvant therapy for resected MSI-H/dMMR colorectal cancer: real-world evidence informing precision strategies.Frontiers in immunology · 2025Article
Corrections and comments
- Commented on by
Authors and funding
27 authors.
Jianwei ZhangDepartment of Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.ORCID 0000-0001-7213-0128
Pan ChiDepartment of Colorectal Surgery, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.ORCID 0000-0002-0004-1174
Lishuo ShiBiomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, The State Key Laboratory of Oncology in South China, Guangzhou, People's Republic of China.ORCID 0000-0002-0715-9941
Long CuiXinhua Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Jinbo GaoUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wanglin LiThe First People's Hospital, Guangzhou City, People's Republic of China.
Hongbo WeiThe Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.ORCID 0000-0002-1809-6544
Longqing ChengThe First People's Hospital, Foshan City, People's Republic of China.
Zonghai HuangZhujiang Hospital, Nanfang University of Medical Science, Guangzhou, People's Republic of China.ORCID 0000-0003-1187-7775
Guangfu CaiGuangdong Provincial Peoples Hospital, Guangzhou, People's Republic of China.
Ren ZhaoRuijin Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Zhongcheng HuangGeneral Hospital, Hunan Province, Changsha, People's Republic of China.
Hongfeng ZhouGuangzhou General Hospital of Guangzhou Military Command, Guangzhou, People's Republic of China.
Yisheng WeiThe Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, People's Republic of China.ORCID 0000-0002-9916-6910
Hao ZhangKuanghua Hospital, Dongguan, People's Republic of China.
Jian ZhengGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
Yan HuangGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
Yue CaiDepartment of Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
Zhiyang ZhouGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
Liang KangGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.ORCID 0000-0001-7062-8280
Meijin HuangGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
Xiaojian WuGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.ORCID 0000-0001-5610-2530
Junsheng PengGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
Donglin RenGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
Ping LanGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.ORCID 0000-0002-5225-5027
Jianping WangGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
Yanhong DengDepartment of Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.ORCID 0000-0001-6873-8026
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present 10-year results of the phase Ⅲ FOWARC trial, which evaluated the efficacy of modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) with or without radiation compared with fluorouracil with radiation in patients with locally advanced rectal cancer. A total of 495 patients age 18-75 years with stage Ⅱ-Ⅲ rectal cancer were randomly assigned to three treatment arms: fluorouracil plus radiotherapy, mFOLFOX6 plus radiotherapy, or mFOLFOX6 alone, followed by surgery and adjuvant chemotherapy. With a median follow-up of 10 years, the 10-year disease-free survival (DFS) rates were 52.5%, 62.6%, and 60.5%, respectively (
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsRectal NeoplasmsAdolescentAdultAgedDisease-Free SurvivalFemaleFluorouracilFollow-Up StudiesHumansLeucovorinMaleMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingFluorouracilLeucovorinOrganoplatinum CompoundsOxaliplatin
Identifiers
PMID
39671537What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.